NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
Hematological Oncology · 2026
DOI: 10.1002/hon.70169 ↗Kurz gefasst
Leserbrief in der Zeitschrift Hematological Oncology, 2026. Verfasst von Calogero Vetro und 22 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Bone Marrow Transplantation Unit, Hospital of Bolzano (SABES-Azienda Sanitaria dell'Alto Adige), Teaching Hospital of Paracelsus Medic…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Isocitrate Dehydrogenase, Leukemia, Myeloid, Acute, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In the AVALON cohort of relapsed/refractory AML treated with venetoclax plus hypomethylating agents, NPM1 and IDH1/2 mutations showed no significant impact on response or survival. These findings indicate that prognostic models for relapsed AML should consider treatment context rather than baseline mutation status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hematology and Bone Marrow Transplantation Unit, Hospital of Bolzano (SABES-Azienda Sanitaria dell'Alto Adige), Teaching Hospital of Paracelsus Medical University, Bolzano, Italy.
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
- Department of Hematology and Sciences Oncology, Institute of Haematology "L. and A. Seràgnoli" S. Orsola, University Hospital in Bologna, Bologna, Italy.
- Division of Hematology, A.O.U. Policlinico "G.Rodolico-S. Marco", Catania, Italy.
- Unità di Ematologia e TCS, Ospedale "Vito Fazzi", Lecce, Italy.
- UOC Oncoematologia, Fondazione IRCCS "Ca'Granda" Ospedale Maggiore Policlinico, Milano, Italy.
ORCID-Profile: Calogero Vetro, Irene Azzali, Cristina Papayannidis, Fanny Erika Palumbo, Nicola Fracchiolla, Patrizia Zappasodi, Luca Maurillo, Giovanni Marconi
Zitieren
APA
Vetro, C., Azzali, I., Petracci, E., Papayannidis, C., Eleuteri, E., Palumbo, F. E., Federico, V., Fracchiolla, N., Zappasodi, P., Martelli, M. P., Giannini, M. B., Brunetti, L., Palmieri, R., Nanni, J., Simonetti, G., Guolo, F., Minetto, P., Maurillo, L., Gigli, F., …, & Marconi, G. (2026). NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort. Hematological Oncology. https://doi.org/10.1002/hon.70169
Vancouver
Vetro C, Azzali I, Petracci E, Papayannidis C, Eleuteri E, Palumbo FE, et al. NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort. Hematological Oncology. 2026. doi:10.1002/hon.70169
BibTeX
@article{Vetro2026,
author = {Vetro, Calogero and Azzali, Irene and Petracci, Elisabetta and Papayannidis, Cristina and Eleuteri, Eleonora and Palumbo, Fanny Erika and Federico, Vincenzo and Fracchiolla, Nicola and Zappasodi, Patrizia and Martelli, Maria Paola and Giannini, Maria Benedetta and Brunetti, Lorenzo and Palmieri, Raffaele and Nanni, Jacopo and Simonetti, Giorgia and Guolo, Fabio and Minetto, Paola and Maurillo, Luca and Gigli, Federica and Billio, Atto and Todisco, Elisabetta and Martinelli, Giovanni and Marconi, Giovanni},
title = {NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort},
journal = {Hematological Oncology},
year = {2026},
doi = {10.1002/hon.70169}
}
EUVIMED